FDA Approves AstraZeneca’s Etcamah, Bringing ctDNA-Guided Treatment to Breast Cancer
The FDA has granted accelerated approval to AstraZeneca’s camizestrant, branded as Etcamah, creating a new approach to treating HR-positive, HER2-negative breast cancer before visible disease progression.
The decision is significant because Etcamah is being introduced based on changes detected through circulating tumor DNA, or ctDNA, rather than waiting for scans to show that the cancer has progressed.
Etcamah is approved in combination with a CDK4/6 inhibitor for patients whose tumors develop an ESR1 mutation while they are receiving first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor.
ESR1 mutations are important because they can make hormone receptor-positive breast cancer less responsive to endocrine therapy. Detecting these mutations through a blood test can therefore provide an earlier signal that treatment may eventually stop working.
The approval is mainly supported by results from the Phase 3 Serena-6 trial. The study evaluated patients who had no radiographic evidence of progression but had developed an ESR1 mutation that was detected through ctDNA testing.
Patients who switched to the Etcamah-based regimen had a 56% lower risk of disease progression or death compared with those who continued their original treatment. Median progression-free survival was 16 months with the new approach versus 9.2 months with continued therapy.
The benefit also extended into the period after the next treatment line. Patients receiving Etcamah had a 23% lower risk of progression on subsequent treatment or death, while overall survival data remained immature but showed a favorable trend.
What makes the approval particularly notable is the regulatory debate surrounding the Serena-6 trial. The FDA had initially questioned whether the study provided the right comparison because many patients would normally receive another oral SERD after their cancer progresses.
The concern was also raised during an FDA advisory committee meeting in April, where experts largely questioned the trial design. The study did not allow patients in the control group to cross over to Etcamah, and only 14% received another oral SERD as subsequent therapy.
AstraZeneca later provided additional ctDNA analyses requested by the FDA. Data presented at ASCO 2026 showed that total ctDNA levels fell by 99% by Week 8 in the Etcamah group, while levels increased by 64% in the control group.
An exploratory analysis also associated a reduction in total ctDNA with a 61% improvement in overall survival. These additional findings helped strengthen the case for using molecular changes as an early signal to change treatment.
The FDA’s decision now gives clinicians the option to act before conventional imaging identifies progression. Instead of waiting for tumors to grow visibly, physicians can potentially use a blood-based molecular signal to change therapy while the disease remains radiographically stable.
The commercial opportunity is also substantial. AstraZeneca estimates that around 37,000 patients with HR-positive metastatic breast cancer in the U.S. receive medicines paired with CDK4/6 inhibitors, while about 30% may develop ESR1 mutations during first-line treatment.
AstraZeneca expects Etcamah to eventually generate more than $5 billion in annual sales. However, the currently approved first-line indication represents only a portion of that ambition, with broader opportunities expected across earlier stages of breast cancer.
Etcamah will also compete with oral SERDs from pharma companies including Menarini Group, Eli Lilly and Roche. Their programs are increasingly focused on using targeted endocrine approaches in earlier breast cancer treatment, making biomarker-guided therapy an important area of competition.
The next major milestone will be the Phase 3 Serena-4 trial, which is evaluating Etcamah as a first-line treatment regimen. Its results could provide further evidence on how broadly AstraZeneca can expand this treatment strategy.
More importantly, the approval could influence how pharmaceutical companies design future oncology trials. If ctDNA can reliably identify emerging resistance before radiographic progression, treatment decisions may increasingly move from reacting to visible disease toward responding to molecular changes earlier.
About AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on discovering, developing and commercializing medicines across oncology, biopharmaceuticals and rare diseases. Its oncology portfolio includes treatments for breast, lung and other cancers. The company continues to invest heavily in targeted therapies and biomarker-led treatment approaches.
Reference: